慢性搔癢症市場－全球及區域分析：按國家/地區分類－分析與預測（2025-2035）

全球慢性搔癢症市場分析與預測（2025-2035）

慢性搔癢是指持續超過六週的持續性、通常較為嚴重的搔癢。

慢性搔癢可能是多種潛在疾病的症狀，包括濕疹、乾癬、肝病、腎臟病和神經系統疾病。慢性搔癢不只是令人煩惱，它還會嚴重影響患者的生活品質，導致睡眠障礙、焦慮甚至憂鬱症。與外部因素（例如昆蟲叮咬）引起的暫時性搔癢不同，慢性搔癢通常與內部因素有關，因此更難治療。它還可能伴隨其他症狀，例如患處發紅、腫脹和疤痕。

慢性搔癢症市場的發展主要受皮膚病和慢性疾病盛行率上升、公眾意識提高、診斷水平提高以及標靶治療進步的推動。慢性搔癢症通常是濕疹、乾癬、肝病和慢性腎臟病等潛在疾病的症狀。隨著全球人口老化和這些疾病盛行率的增加，對有效治療方法的需求也隨之成長。例如，根據美國皮膚病學會統計，光在美國就有超過3,160萬人患有濕疹。這些人口結構的變化正在推動人們對緩解這些疾病引起的搔癢和不適症狀的治療方法的需求。

此外，慢性搔癢日益被認為是重要的臨床問題。醫療專業人員對慢性搔癢與多種疾病的關聯有了更深入的了解，患者也越來越傾向於尋求醫療幫助，尤其是那些因持續性搔癢而影響生活品質的患者。診斷技術的進步和患者意識提升的提高也促進了對搔癢治療需求的成長。

儘管目前有多種治療方法可以治療慢性搔癢，但經美國食品藥物管理局 (FDA)核准的針對搔癢的標靶治療數量仍然有限，這限制了患者的治療選擇。儘管研究取得了進展，但美國皮質類食品藥物管理局和抗組織胺等治療方法仍然被廣泛使用，然而這些方法往往無法解決搔癢的根本原因，因此在長期治療中效果有限。

此外，許多現有的治療慢性搔癢的藥物，例如皮質類固醇和抗組織胺藥，都伴隨皮膚變薄、嗜睡和感染疾病風險增加等副作用，這些副作用會影響患者對治療方案的依從性。長期使用全身性藥物可能導致併發症，尤其是在老年患者中，這會妨礙患者完全堅持治療方案。慢性搔癢也常被漏診或誤診，因為它常被歸因於其他皮膚疾病或僅被視為一種症狀。這可能導致患者直到症狀惡化才尋求治療或接受適當的護理，從而限制了有效治療方法的市場潛力。

生物製藥療法在治療慢性搔癢方面越來越受歡迎，尤其是在濕疹、乾癬和其他皮膚病患者中。此外，人們越來越關注針對搔癢特定分子機制的標靶藥物的研發。與傳統的全身性治療相比，這些治療方法有望在副作用最小的情況下提供長期的症狀緩解。

此外，隨著我們對搔癢分子路徑的了解不斷深入，市場正朝著基於搔癢具體病因的精準醫療方向發展。這種方法能夠透過針對潛在病因（例如濕疹或肝病）而非僅僅掩蓋症狀，來有效控制慢性搔癢。

市場上的競爭策略包括擴大現有藥物的適應症、引入新的生物製藥以及改進局部治療的配方。

本報告對全球慢性搔癢症市場進行了分析，概述了市場情況，並介紹了區域趨勢和參與該市場的公司的概況。

目錄

執行摘要

第1章 全球慢性搔癢症市場：產業展望

• 市場概覽
• 流行病學分析
• 監管狀態
• 主要趨勢
• 臨床試驗分析
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場約束
  • 市場機遇

2. 全球慢性搔癢症市場（按地區分類，單位：百萬美元，2023-2035年）

• 北美洲
  • 市場動態
  • 市場規模及預測
• 歐洲
  • 市場動態
  • 市場規模及預測
• 亞太地區
  • 市場動態
  • 市場規模及預測

3. 慢性搔癢症市場：競爭格局與公司概況

• 競爭格局
  • 關鍵策略和發展（按公司分類）
• 公司簡介
  • Nuogen Pharma
  • Sanofi
  • GalaxoSmithKline plc
  • Chugai Pharmaceutical
  • Galderma
  • Mirum Pharmaceuticals
  • 其他

第4章調查方法

Global Chronic Pruritus Market, Analysis and Forecast: 2025-2035

Chronic pruritus is a persistent and often severe form of itching that lasts for more than six weeks. It can be a symptom of various underlying medical conditions, including eczema, psoriasis, liver disease, kidney disease, and neurological disorders. Chronic pruritus is more than just an irritation; it can significantly affect a person's quality of life, leading to sleep disturbances, anxiety, and even depression. Unlike temporary itching caused by external factors (like an insect bite), chronic pruritus is often associated with internal causes, making it more challenging to treat. It can occur alongside other symptoms such as redness, swelling, or scarring in the affected areas.

The chronic pruritus market is driven by increasing prevalence of skin disorders and chronic conditions, increasing awareness and diagnosis, and advancement in targeted therapies. Chronic pruritus is often a symptom of underlying conditions like eczema, psoriasis, liver diseases, and chronic kidney disease. As the global population ages and the prevalence of these conditions increases, the demand for effective treatments for chronic pruritus has also grown. For instance, eczema affects more than 31.6 million people in the U.S. alone, according to the American Academy of Dermatology. This demographic shift is driving demand for therapies to manage itching and discomfort associated with these conditions.

Moreover, there is a growing recognition of chronic pruritus as a significant clinical issue. Healthcare professionals are more attuned to its link to various diseases, and patients are increasingly seeking medical attention for persistent itching, especially when it affects quality of life. Advances in diagnostic techniques and greater patient awareness contribute to the rising demand for pruritus treatments.

Although there are multiple treatments available for managing chronic pruritus, the FDA has yet to approve many targeted therapies specifically for pruritus, which can limit treatment options for patients. Despite advances in research, treatments like topical corticosteroids and antihistamines are still commonly used but often fail to address the underlying causes of itching, leading to limited effectiveness for long-term management.

In addition, many of the existing treatments for chronic pruritus, such as corticosteroids and antihistamines, come with side effects like skin thinning, drowsiness, and increased risk of infection, which can impact patient adherence to treatment regimens. Long-term use of systemic medications, particularly in the elderly, can lead to complications, which may deter patients from fully complying with treatment plans. Also, chronic pruritus is often underdiagnosed or misdiagnosed, as it is frequently attributed to other dermatological conditions or simply managed as a symptom rather than a condition in its own right. This limits the market potential for effective therapies, as patients may not seek treatment or receive appropriate care until their condition worsens.

Biologic therapies are becoming increasingly popular for treating chronic pruritus, especially in patients with eczema, psoriasis, and other skin conditions. Moreover, there is a growing focus on the development of targeted drugs that address the specific molecular mechanisms of pruritus. These therapies offer potential for long-term relief with minimal side effects compared to traditional systemic treatments.

Furthermore, with a better understanding of the molecular pathways involved in pruritus, the market is seeing a shift toward precision medicine based on the specific cause of itching. This approach allows for more effective management of chronic pruritus by targeting the underlying condition, such as eczema or liver disease, rather than just masking the symptom.

Competitive strategies within the market include expanding the therapeutic indications of existing drugs, introducing new biologics, and refining formulations of topical treatments.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Chronic Pruritus Market: Industry Outlook

• 1.1 Market Overview
• 1.2 Epidemiological Analysis
• 1.3 Regulatory Landscape
• 1.4 Key Trends
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraint
  • 1.6.4 Market Opportunities

2. Global Chronic Pruritus Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Sizing and Forecast
    • 2.1.2.1 North America Chronic Pruritus Market, by Country
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Sizing and Forecast
    • 2.2.2.1 Europe Chronic Pruritus Market, by Country
      • 2.2.2.1.1 Germany
      • 2.2.2.1.2 U.K.
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Sizing and Forecast
    • 2.3.2.1 Asia-Pacific Chronic Pruritus Market, by Country
      • 2.3.2.1.1 Japan

3. Chronic Pruritus Market: Competitive Landscape and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments, by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations, and Business Expansions
• 3.2 Company Profiles
  • 3.2.1 Nuogen Pharma
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers/End-Users
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 Sanofi
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers/End-Users
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 GalaxoSmithKline plc
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Top Competitors
    • 3.2.3.4 Target Customers/End-Users
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View
  • 3.2.4 Chugai Pharmaceutical
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products / Product Portfolio
    • 3.2.4.3 Top Competitors
    • 3.2.4.4 Target Customers/End-Users
    • 3.2.4.5 Key Personnel
    • 3.2.4.6 Analyst View
  • 3.2.5 Galderma
    • 3.2.5.1 Overview
    • 3.2.5.2 Top Products / Product Portfolio
    • 3.2.5.3 Top Competitors
    • 3.2.5.4 Target Customers/End-Users
    • 3.2.5.5 Key Personnel
    • 3.2.5.6 Analyst View
  • 3.2.6 Mirum Pharmaceuticals
    • 3.2.6.1 Overview
    • 3.2.6.2 Top Products / Product Portfolio
    • 3.2.6.3 Top Competitors
    • 3.2.6.4 Target Customers/End-Users
    • 3.2.6.5 Key Personnel
    • 3.2.6.6 Analyst View
  • 3.2.7 Others

4. Research Methodology

List of Figures

• Figure: Chronic Pruritus Market (by Scenario), $Million, 2024, 2030, and 2035
• Figure: Global Chronic Pruritus Market, 2024 and 2035
• Figure: Global Chronic Pruritus Market Key Trends, Impact Analysis, 2023-2035
• Figure: North America Chronic Pruritus Market, $Million, 2023-2035
• Figure: Europe Chronic Pruritus Market, $Million, 2023-2035
• Figure: Asia-Pacific Chronic Pruritus Market, $Million, 2023-2035

List of Tables

• Table: Market Snapshot
• Table: Global Chronic Pruritus Market Dynamics, Impact Analysis
• Table: Global Chronic Pruritus Market (by Region), $Million, 2023-2035